Anaptysbio Inc SEC Filings

Eric J. Loumeau, Chief Legal Officer of AnaptysBio, Inc. (ANAB), reported both purchases and sales of company common stock on 09/30/2025. He acquired 5,000 shares by exercising employee stock options at an exercise price of $14.02 and an additional 1,325 shares under the company ESPP included in the reported holdings, bringing his post-transaction direct ownership to 17,328 shares. He also sold 8,240 shares at $29.00 per share under a 10b5-1 trading plan adopted April 11, 2025.

The Form 4 shows he retains outstanding options to purchase 68,000 shares exercisable under the option described and additional unvested options aggregating up to 422,310 shares that vest per their terms. Transactions were routine insider activity documented under Section 16 reporting rules.

Form 144 notice for ANAPTYSBIO, Inc. (ANAB) shows a proposed sale of 8,240 common shares totaling an aggregate market value of $238,960.00. The sale is reported through Morgan Stanley Smith Barney LLC on the NASDAQ with an approximate sale date of 09/30/2025. The securities were acquired in two transactions: 3,240 restricted shares issued on 01/06/2024 (paid at issuance) and 5,000 shares from a stock option exercise on 09/30/2025 (paid in cash). No securities of the issuer were sold by the reporting person in the prior three months, and the filer represents no undisclosed material adverse information.

AnaptysBio's board has approved plans to explore separating its business into two independent, publicly traded companies. The company says the separation is expected to occur by the end of 2026. Management will host a conference call using a slide presentation to discuss the potential separation; the presentation is included as an exhibit. A press release describing the board action is also attached as an exhibit. The disclosure notes that the Item 7.01 information and the presentation are not deemed "filed" for Section 18 purposes.

Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of 1,426,893 shares of AnaptysBio, Inc. (ANAB), representing 5.1% of the outstanding common stock. The Schedule 13G discloses shared voting and dispositive power over these shares with no sole voting or dispositive power reported. The filing indicates the securities are held by entities subject to voting control and investment discretion by Millennium and related managers.

The filing includes a Joint Filing Agreement dated September 22, 2025, and certifications that the holdings were not acquired to change or influence control of the issuer. Addresses for the reporting persons and CUSIP 032724106 are provided.

ANAPTYSBIO, Inc. (ANAB) director John A. Orwin received a grant of 1,300 restricted stock units (RSUs) reported on Form 4 with a transaction date of 09/15/2025. Each RSU represents a contingent right to one share of common stock to be settled for no consideration. The filing shows 10,665 shares beneficially owned by Mr. Orwin following the reported transaction. The RSUs are subject to a time-based vesting schedule stated in the filing: one‑third vested on 09/15/2024, one‑third on 09/15/2025 and the final one‑third on 09/15/2026, each tranche conditioned on continued service. The Form 4 was signed by an attorney‑in‑fact on 09/17/2025.

Renton Hollings, a director of AnaptysBio (ANAB), exercised options and sold shares under a Rule 10b5-1 plan. On 08/08/2025 he exercised options with an exercise price of $6.93 to acquire 10,231 shares and sold portions of those shares: 3,110 sold at a weighted-average price of $19.44 (sales ranged $19.375–$19.46) and 7,121 sold at a weighted-average price of $19.696 (sales ranged $19.48–$20.46). The sales were effected pursuant to a 10b5-1 trading plan adopted March 14, 2024.

Additional details: the exercised options include a 2015 grant that is fully vested and exercisable through its expiration on August 13, 2025. The filing notes remaining options to purchase 10,231 shares referenced in Table II and additional options to purchase up to an aggregate of 101,820 shares. The Form 4 was filed with a signature dated 08/12/2025 by an attorney-in-fact.

AnaptysBio, Inc. (ANAB) Form 144 shows an intended sale of 10,231 common shares with an aggregate market value of $200,712.78 to be executed on or about 08/08/2025 through Morgan Stanley Smith Barney on NASDAQ. The filing states these shares were acquired by a stock option exercise on 08/08/2025 with payment in cash. The notice also discloses prior sales by the same person, HOLLINGS C RENTON: 20,925 shares sold 07/02/2025 for $493,189.70 and 3,015 shares sold 06/18/2025 for $72,269.55. The signer represents there is no undisclosed material adverse information.

AnaptysBio is registering 1,650,000 additional shares of its common stock to be available under the Amended and Restated 2017 Equity Incentive Plan following stockholder approval. The filing makes those shares available for future awards to employees and directors and incorporates prior S-8 registrations and related company filings on file with the SEC.